Data from before the 2000s indicate that the majority of incident cardiovascular disease (CVD) events occur among US adults with systolic and diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg. Over the past several decades, BP has declined and hypertension control has improved.
O
bservational studies have demonstrated graded associations between higher systolic and diastolic blood pressure (SBP/DBP) and increased cardiovascular disease (CVD) risk. 1 Since 1993, Joint National Committee guidelines in the United States have categorized adults with SBP ≥140 mm Hg or DBP ≥90 mm Hg as having hypertension. [2] [3] [4] Although most US adults have SBP/DBP <140/90 mm Hg, data from before the 2000s indicate that a majority of incident stroke, coronary heart disease (CHD), and heart failure (HF) events occur among US adults with SBP/DBP ≥140/90 mm Hg (Table 1) . [5] [6] [7] [8] [9] [10] [11] For example, data from the ARIC study (Atherosclerosis Risk in Communities), CHS (Cardiovascular Health Study), and FHS (Framingham Heart Study) indicate that 77% of incident strokes, 69% of incident myocardial infarctions (MIs), and 74% of HF events occurred among adults with SBP/DBP ≥140/90 mm Hg. 11 However, over the past several decades, the mean SBP and DBP have declined among US adults. 12 Also, between 1988-1991 and 2011-2012 , the percentage of US adults who have SBP <140 mm Hg and DBP <90 mm Hg has increased from 24% to 52% among the overall population with hypertension and from 45% to 70% among those with hypertension taking antihypertensive medication. 13, 14 Given the shift in BP distribution and hypertension control among US adults, the majority of incident CVD events may now occur among people with SBP/DBP <140/90 mm Hg. This change would highlight the need to focus CVD prevention on further BP reduction and treatment of other major CVD risk factors among adults with SBP/DBP <140/90 mm Hg. Therefore, the purpose of the current study was to determine the percentage of incident CVD events occurring among adults with SBP/ DBP <140/90 mm Hg. Additionally, to identify opportunities to further reduce CVD risk among adults with SBP/ DBP <140/90 mm Hg, we examined the use of statins among participants with an indication for a statin. We also calculated the percentage of adults with SBP between 120 mm Hg and 139 mm Hg who meet eligibility criteria for the SPRINT (Systolic Blood Pressure Intervention Trial) because this large randomized trial showed a SBP target goal of 120 mm Hg versus 140 mm Hg substantially lowered risk for CVD and all-cause mortality. 15 
METHODS

Study Populations
We pooled data from 3 large contemporary US cohorts: the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), the MESA (Multi-Ethnic Study of Atherosclerosis), and the JHS (Jackson Heart Study). The study design, recruitment, and data-collection procedures used in these studies have been described in detail previously. [16] [17] [18] [19] A brief description of each cohort is presented in online-only Data Supplement Table I .
The current analyses were restricted to participants without a history of stroke, CHD, HF, or atherosclerotic CVD procedure to examine incident CVD events ( Figure 1 ). Complete information on antihypertensive medication use and SBP and DBP measurements from the baseline visit for each study were required for inclusion in the current analyses. Additionally, 377 participants in the REGARDS study and 32 participants in the MESA study without follow-up for stroke, CHD, and HF events were excluded. After these criteria were applied, data were available for 31 856 participants (REGARDS, n=21 208; MESA, n=6779; JHS, n=3869). REGARDS, JHS, and MESA were each approved by the appropriate institutional review boards, and written informed consent was obtained from all participants.
Data Collection
For each cohort, we used interview and examination data collected at baseline and follow-up data for CVD events. Detailed methods for the baseline data collection in the REGARDS study, 18 MESA, 17 and JHS 16, 19 have been described previously.
Clinical Perspective
What Is New? 
What Are the Clinical Implications?
• Because the majority of CVD events are now occurring among adults with SBP/DBP <140/90 mm Hg, additional BP reduction and treatment of other major CVD risk factors should be considered for this population, particularly among those with high CVD risk.
• Findings from SPRINT indicate that treatment to a SBP target of 120 mm Hg versus 140 mm Hg prevents CVD and reduces the risk for mortality among adults with high CVD risk.
• Also, the HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) provides evidence that statin therapy is well tolerated and lowers the risk of CVD.
BP Measurement
BP was measured in REGARDS, MESA, and JHS by trained study staff using standardized methods. 17, 19, 20 In REGARDS, SBP and DBP were measured twice, 30 seconds apart, using an aneroid sphygmomanometer (American Diagnostic Corporation) after the participant had been seated for 5 minutes. 18, 20, 21 These measurements were averaged for analysis. In MESA, SBP and DBP were measured 3 times at 2-minute intervals using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (GE Medical Systems Information Technologies, Inc.) after participants rested for 5 minutes in a seated position. 22 The second and third measurements were averaged. 17, 22 In JHS, at the baseline assessment, SBP and DBP were measured twice, separated by 1 minute, with an appropriate cuff size using a Hawksley random-zero sphygmomanometer (Hawksley and Sons Ltd) after a participant had rested for ≥5 minutes. These measurements were averaged for analysis. 19 In subsequent JHS visits, an Omron HEM-907XL (Omron Healthcare Inc.) automatic oscillatory device was used to measure BP following the same measurement protocol as used for the random-zero sphygmomanometer. All BP readings taken in JHS with the random-zero sphygmomanometer device were calibrated to the automatic oscillatory device after a BP comparability study. 23 Participants were categorized as having SBP <140 mm Hg and DBP <90 mm Hg (SBP/DBP <140/90 mm Hg) or SBP ≥140 mm Hg or DBP ≥90 mm Hg (SBP/DBP ≥140/90 mm Hg) regardless of antihypertensive medication use. As described below, analyses were performed for participants overall and by antihypertensive medication use.
Study Variables
Age, race/ethnicity, sex, antihypertensive medication use, antihyperglycemic medication use (insulin or oral hypoglycemic medication), and current cigarette smoking status were self-reported. Obesity was defined as a body mass index ≥30.0 kg/m 2 . Using data collected during visits for each study, body mass index was calculated as weight in kilograms divided by height in meters squared. Total and high-density lipoprotein-cholesterol and triglycerides were measured from fasting blood samples (online-only Data Supplement Table  I ). Low-density lipoprotein-cholesterol was calculated using the Friedewald equation. 24 The definitions of diabetes mellitus used in each cohort are provided in online-only Data Supplement Table I . We calculated 10-year predicted CVD risk using the Pooled Cohort Risk Equations. 25 Indications for statins included having diabetes mellitus, low-density lipoprotein-cholesterol ≥190 mg/dL, or a 10-year CVD risk ≥7.5%.
26
Statin use was determined by pill bottle review. Estimated glomerular filtration rate was calculated using the CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration).
27
CVD Outcomes
The primary outcome for the current study was incident CVD, defined by the first occurrence of a fatal or nonfatal stroke, nonfatal MI, fatal CHD, or nonfatal HF. Detailed descriptions of the adjudication process in REGARDS, 18, 28, 29 MESA, 17, 30 and JHS 31 have been published previously. In brief, study participants or their proxies were contacted to identify hospitalizations and possible CVD events at 6-month intervals for CHD indicates coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; and SBP, systolic blood pressure. *ICD-8 codes 400.0 to 445.9, which included coronary heart disease, stroke or transient ischemic attacks, peripheral artery disease, and heart failure. †Coronary heart disease, stroke or transient ischemic attacks, peripheral artery disease, and heart failure. ‡Myocardial infarction, stroke, and cardiovascular disease-related death. §Myocardial infarction, stroke, heart failure, coronary insufficiency, and sudden cardiovascular disease-related death.
ORIGINAL RESEARCH ARTICLE REGARDS, 9-to 12-months intervals for MESA, and annually for JHS. If a hospitalization for CVD was suspected, then the event was adjudicated by trained physicians. Deaths were detected by report from next of kin, the National Death Index, or through online sources (eg, Social Security Death Index). Interviews were conducted with proxies or next of kin regarding the circumstances surrounding death, including the presence of chest pain. Cause of death was adjudicated using information obtained from proxies, medical history, death certificates, and autopsy reports. Incident stroke events included the first occurrence of a definite nonfatal or fatal stroke. [31] [32] [33] Incident CHD events were defined as the first occurrence of a definite or probable nonfatal MI or definite or probable fatal CHD event. 28, 31, 32 Incident HF events were defined as a definite or probable HF hospitalization. 17, 29, 31 More details on the definitions for incident stroke, CHD, and HF are presented in online-only Data Supplement Table I. Adjudicated events 
Statistical Analysis
All analyses were performed for participants overall and for those taking and not taking antihypertensive medication, separately. Participant characteristics were calculated with the statistical significance of differences between those with SBP/DBP <140/90 mm Hg versus SBP/DBP ≥140/90 mm Hg determined using t tests and χ 2 tests for continuous and categorical variables, respectively. P values <0.05 were considered statistically significant. The percentage of incident CVD, stroke, CHD, and HF events occurring among participants with SBP/DBP <140/90 mm Hg and SBP/DBP ≥140/90 mm Hg, separately, was calculated overall and in subgroups defined by age, sex, and race/ethnicity. Results from individual studies were pooled to obtain a weighted estimate using a random-effects model meta-analysis for proportions. 34 Next, incidence rates for CVD, stroke, CHD, and HF were calculated. These rates were calculated for the overall population and in subgroups defined by age, sex, race/ethnicity, current smoking, and diabetes mellitus status within each study, with pooled weighted estimates calculated using random-effects models. 35 The statistical significance of differences in percentages and incidence rates across subgroups and by antihypertensive medication use status was calculated using Poisson regression models within each study and using random-effects models for the pooled results. Robust variance estimators were used in Poisson regression models when comparing percentages. 36 To investigate potential opportunities to lower CVD risk among adults taking antihypertensive medication with SBP/ DBP <140/90 mm Hg, we calculated the percentage of participants with an indication for statins who were taking a statin and the percentage with SBP ≥120 mm Hg and <140 mm Hg who were SPRINT eligible. SPRINT eligibility was defined as being ≥50 years of age, having SBP between 130 and 180 mm Hg (depending on the number of antihypertensive medications prescribed), having high CVD risk, being free of diabetes mellitus, end-stage renal disease, overt proteinuria, and not having a history of stroke. 15 High CVD risk criteria included the presence of an estimated glomerular filtration rate of 20 to 59 mL/min/1.73 m 2 , a 10-year Framingham risk score for CVD ≥15%, or ≥75 years of age.
Several sensitivity analyses were conducted. First, we calculated the percentage of incident CVD, stroke, CHD, and HF events that occurred among participants with SBP/DBP <140/90 mm Hg in MESA and JHS, updating BP and antihypertensive medication use status to the nearest examination visit before their incident CVD event, rather than utilizing values from the baseline examination. We also calculated incidence rates updating BP and antihypertensive medication use status using data collected during follow-up visits. Second, to assess the percentage of CVD events that occurred at SBP/ DBP <140/90 mm Hg in a nationally representative sample, we utilized NHANES (National Health and Nutrition Examination Survey) data from 2001 to 2008 with mortality follow-up through 2011. Using these data, we determined the percentage of CVD deaths occurring among US adults with SBP/DBP <140/90 mm Hg and CVD mortality rates per 1000 person years of observation. The analysis of NHANES data accounted for its complex survey design and were weighted to the noninstitutionalized US population. 37 Cause of death in NHANES was determined by linking the data to the National Death Index. 37 Third, we calculated the percentage of incident CVD, stroke, CHD, and HF events that occurred among participants with SBP/DBP <130/80 mm Hg and, separately, SBP/DBP <150/100 mm Hg. Fourth, we determined the percentage of incident CVD events among participants with SBP/DBP <140/90 mm Hg after excluding Hispanic and Chinese MESA participants because the REGARDS study and JHS enrolled only black and white adults. Fifth, the REGARDS study used an aneroid sphygmomanometer to measure BP in the home. Previous studies have reported only small differences in BP measured by aneroid and oscillometric methods. 38, 39 However, BP measured in the home may be lower compared with BP measured in the clinic. 40 Therefore, we determined the proportion of incident events that occurred among REGARDS study participants with SBP <135 mm Hg and DBP <85 mm Hg. All analyses were conducted using SAS Version 9.4 (SAS Institute) and STATA Version 13 (StataCorp).
RESULTS
Baseline Characteristics
After pooling participants from REGARDS, MESA, and JHS, 78.3% of the sample had SBP/DBP <140/90 mm Hg ( 
Percentage of Incident Events Occurring in Participants With SBP/DBP ≤140/90 mm Hg
Over a mean follow-up time of 7.7 years (maximum follow-up 13.5 years), 2584 participants had an incident CVD event. Overall, 63.0% (95% confidence interval [CI], 54.9-71.1) of incident CVD events occurred in participants with SBP/DBP <140/90 mm Hg (Figure 2 , top; online-only Data Supplement Table III) . Within every age, sex, and race/ethnicity subgroup, the majority of incident CVD events occurred in participants with SBP/DBP <140/90 mm Hg. The percentage of incident CVD events that occurred among participants with SBP/DBP <140/90 mm Hg was lower among those taking versus not taking antihypertensive medication. The majority of incident stroke, CHD, and HF events occurred in participants with SBP/DBP <140/90 mm Hg overall and also among participants taking and not taking antihypertensive medication ( Figure 2 , middle and lower; online-only Data Supplement Table III) . Overall, 66.0% (95% CI, 63.6-68.3), 54.6% (95% CI, 51.0-58.2), and 68.6% (95% CI, 63.6-73.7) of incident CVD events in REGARDS, MESA, and JHS, respectively, occurred among participants with SBP/DBP <140/90 mm Hg (online-only Data Supplement Table IV) .
Incidence Rates for CVD, Stroke, CHD, and HF Events
The incidence of CVD among participants with SBP/DBP <140/90 mm Hg and SBP/DBP ≥ 140/90 mm Hg was 8.0 (95% CI, 6.7-9.2) and 18.1 (95% CI, 16.7-19.6) per 1000 person-years, respectively (Table 3) . Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg and SBP/DBP ≥140/90 mm Hg, the incidence of CVD was 11.9 (95% CI, 11.1-12.7) and 19.9 (95% CI, 18.3-21.5) per 1000 person-years, respectively. Among participants who were not taking antihypertensive medication, the incidence of CVD was 5.7 (95% CI, 3.9-7.5) per 1000 person-years for those with SBP/DBP <140/90 mm Hg and 15.7 (95% CI, 13.2-18.2) per 1000 person-years for those with SBP/DBP ≥140/90 mm Hg.
ORIGINAL RESEARCH ARTICLE online-only Data Supplement Table V through VII provide incidence rates for CVD, stroke, CHD, and HF events for the REGARDS study, MESA and JHS, respectively.
Statin Use and SPRINT Eligibility
Among participants who were taking antihypertensive medication with SBP/DBP <140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) had an indication for a statin of whom 33.2% (95% CI, 32.1-34.3) were taking a statin (Table 4) . For participants with SBP ≥120 mm Hg and <140 mm Hg who were taking antihypertensive medication, 19.5% (95% CI, 18.5-20.5) met the SPRINT eligibility criteria.
Sensitivity Analyses
After updating BP and antihypertensive medication use status to the nearest examination visit before an incident CVD event, 59.9% (95% CI, 56.3-63.4) and 62.7% (57.5-68.0) of incident CVD events occurred among MESA and JHS participants with SBP/DBP <140/90 mm Hg, respectively (online-only Data Supplement 
DISCUSSION
Several important findings are evident from the current pooled analysis of 3 contemporary US cohort studies. First, >60% of incident CVD events occurred in participants with SBP/DBP <140/90 mm Hg. This finding represents a fundamental shift from previous decades when the majority of incident CVD events occurred among US adults with SBP/DBP ≥140/90 mm Hg. Second, as expected from previous research, the incidence rate of CVD was higher among adults with SBP/DBP ≥140/90 mm Hg compared with participants with SBP/ DBP <140/90 mm Hg. However, a majority of individuals with SBP/DBP <140/90 mm Hg had a 10-year predicted CVD risk ≥7.5%. Third, only 33.2% of participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg and an indication for statins were taking one at the baseline examination of the 3 cohorts. Finally, 19.5% of participants with SBP between 120 mm Hg and 139 mm Hg who were taking antihypertensive medication met the eligibility criteria for SPRINT and may benefit from a SBP target goal of 120 mm Hg. The finding that the majority of incident CVD events in the modern era occur in participants with SBP/DBP <140/90 mm Hg represents a change from studies conducted in prior eras. In US cohort studies from the 1960s through the 1990s, a majority of incident CVD events occurred among adults with SBP/DBP ≥140/90 mm Hg. [5] [6] [7] [8] [9] [10] [11] The results of the current study, which included contemporary population-based and nationally representative samples, are consistent with the increasing awareness, treatment, and control of hypertension that has occurred in the United States over the past several decades. 13, 14 The US NHANES data indicate that from 1988-1991 to 2011-2012, awareness of hypertension among adults increased from 69% to 82% ORIGINAL RESEARCH ARTICLE and treatment rates increased from 53% to 75%. 13, 14 Also, the percentage of US adults with controlled SBP and DBP increased substantially over this time frame. 13 When NHANES data were examined in the current study, the majority of CVD mortality occurred among individuals with SBP/DBP <140/90 mm Hg. In contrast to these findings, the Global Burden of Hypertension and Systolic Blood Pressure study reported that most CVD deaths worldwide occur at SBP ≥140 mm Hg. 41 Data on CVD deaths were not presented separately for the United States. In the GBS (Global Burden Study), the majority of disability-adjusted life-years lost in the United States occurred at a lower level of SBP compared with other countries and regions, indicating that the United States is an outlier. The current study suggests that this may extend from disability-adjusted lifeyears lost to incident CVD events. Elevated BP is a well-established risk factor for stroke, CHD, and HF. 1 Although the majority of CVD events occurred among participants with SBP/DBP <140/90 mm Hg in the current study, participants with SBP/ DBP ≥140/90 mm Hg had a higher incidence of CVD. Among participants not taking antihypertensive medication, the incidence of CVD was almost 3 times higher for those with SBP/DBP ≥140/90 mm Hg versus SBP/DBP <140/90 mm Hg. Further improving BP control among US adults has the potential to reduce CVD incidence.
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More than 50% of participants with SBP/DBP <140/90 mm Hg had a 10-year predicted CVD risk ≥7.5%. Among those individuals taking antihypertensive medication, >75% with SBP/DBP <140/90 mm Hg had a 10-year CVD risk ≥7.5%, demonstrating that a large percentage of adults are at increased risk for CVD events. Previous studies have shown that controlling BP to <140/90 mm Hg using antihypertensive medication does not return CVD risk to the level of individuals with the same BP without antihypertensive treatment. 42, 43 These data highlight the need for primordial prevention of hypertension, earlier detection and treatment of hypertension, and additional CVD risk reduction strategies for adults with hypertension once BP control has been achieved.
Statins may be underutilized among adults taking antihypertensive medication with SBP/DBP <140/90 mm Hg. The 2013 American College of Cardiology/ American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommends statin use for the primary prevention of CVD among adults with diabetes mellitus, low-density lipoprotein-cholesterol ≥190 mg/ dL, or a 10-year predicted CVD risk ≥7.5%. 26 Although >75% of participants who were taking antihypertensive medication with SBP/DBP <140/90 mm Hg had an indication for a statin, only 33% of these participants were taking one. The baseline exams for the current study occurred before the 2013 American College of Cardiology/American Heart Association guideline was published. Results from the HOPE-3 trial (Heart Outcomes Prevention Evaluation 3) suggest that long-term statin use is effective for CVD risk reduction. 44 Specifically, over a median follow-up of 5.6 years in HOPE-3, randomization to 10 mg dose of rosuvastatin daily versus placebo was associated with a 24% CVD risk reduction. Statin medication has also been found to be cost-effective. 45 SPRINT provides evidence for another risk-reduction strategy among adults with hypertension and SBP/ DBP <140/90 mm Hg. 15 SPRINT demonstrated a 25% reduction in CVD events, a 38% reduction in HF, and a 27% reduction in mortality among participants randomized to a SBP target goal of 120 mm Hg compared with their counterparts randomized to the conventional SBP goal of 140 mm Hg. 15 In addition, intensive BP management as tested in SPRINT was determined to be cost-effective at a ratio of $23 777 per qualityadjusted life-year gained. 46 In the current study, 19.5% of participants with SBP between 120 and 139 mm Hg who were taking antihypertensive medication met the SPRINT eligibility criteria. Although absolute risk and cost-effectiveness should be considered when making treatment decisions, these individuals may benefit from a lower SBP target goal.
The current study has a number of strengths. We used data from 3 contemporary population-based cohort studies, and the consistency of results across studies and demographic characteristics suggests that these findings may have a high degree of generalizability. Also, BP was measured using a standardized protocol in each study, and CVD events were adjudicated by trained physicians. The current study should be interpreted in the context of known and potential limitations. Although protocols for measuring variables across studies were similar, there were differences including the devices used to measure BP. The REGARDS study used an aneroid sphygmomanometer to measure BP in the home. Although previous studies have reported only small differences in BP measured by aneroid and oscillometric methods, 38, 39 this approach may have resulted in lower BP readings compared with MESA and JHS. However, the majority of CVD events occurred among participants with SBP/DBP <140/90 mm Hg in each study. Also, although we were able to update BP levels and antihypertensive medication use for MESA and JHS participants in sensitivity analyses, the REGARDS study second in-home visit was conducted from May 2013 to November 2016, and outcomes in the REGARDS study have only been adjudicated through December 31, 2012. Therefore, we were unable to analyze data from the follow-up visit for the REGARDS study. Additionally, BP was only measured at a single visit. BP varies from day to day, and some participants may have been misclassified as having SBP/DBP <140/90 mm Hg. However, previous studies report that BP is lower when based on the average of measurements obtained across multiple clinic visits compared with a single visit. 47, 48 Therefore, the percentage of CVD events occurring at SBP/DBP <140/90 mm Hg is likely higher than we estimated in the current study. We did not have information on the cumulative burden of BP in participants before the baseline examination. Prior studies provide evidence that the cumulative burden of BP assessed across the lifespan, rather than measurements from individual visits, may be more strongly associated with subclinical markers of CVD and future CVD events. 43, 49 Finally, although the cohorts included in the current analysis were population-based, they do not provide nationally representative data. However, we analyzed data from the NHANES and showed that the majority of CVD deaths occurred among US adults with SBP/DBP <140/90 mm Hg.
CONCLUSIONS
In this pooled analysis of adults without a history of CVD enrolled in 3 large population-based US cohorts conducted in the 2000s, >60% of incident CVD events occurred among participants with BP <140/90 mm Hg. These findings represent a fundamental change from previous studies conducted in the 1980s and 1990s, wherein the majority of CVD events occurred among participants with BP ≥140/90 mm Hg. The incidence of CVD was higher for adults with SBP/DBP ≥140/90 mm Hg, reinforcing the importance of improving BP control among this population. Efforts directed at lowering BP and reducing CVD risk among adults with SBP/ DBP <140/90 mm Hg are needed, particularly among those with a 10-year CVD risk ≥7.5%.
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